Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1792, Issue 9, Pages 841-843Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbadis.2008.11.012
Keywords
Mannose supplementation; Heparin therapy; Congenital disorder of glycosylation; Hepatomegaly; PMI; Phosphomannose isomerase
Funding
- Euroglycanet [LSHM-CT2005-512131]
- Fondation Jerome Lejeune
Ask authors/readers for more resources
Phosphomannose isomerase (PMI) deficiency or congenital disorders of glycosylation type Ib (CDG Ib) is the only CDG that can be treated. Despite variable severity leading to dramatically different prognoses, clinical presentation is relatively homogeneous with liver and digestive features associated with hyperinsulinism and inconstant thrombosis. A feature of CDG is that coagulation factors are decreased. In our experience, mannose given orally at least 4 times per day not only transformed lethal CDG Ib into a treatable disease, but also improved the general condition and digestive symptoms of all reported patients but one. Liver disease. however, still persisted. Heparin can be used as an alternative to mannose in certain patients, particularly in the treatment of enteropathy. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available